Prostate-Specific Antigen and Prostate Cancer in Gender-Affirming Hormone Therapy for Transgender or Nonbinary Individuals
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2024.09.039 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Kylie M Morgan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California; Center for Health Equity and Educati…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Gonadotropin-Releasing Hormone, Transgender Persons. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The effects of gender-affirming hormone therapy on prostate-specific antigen (PSA) and prostate cancer incidence in transgender or nonbinary individuals (TGNB) born with prostate glands remain uncharacterized. METHODS AND MATERIALS: The cohort included 1024 self-identified TGNB individuals assigned male at birth who received PSA testing in the Veterans Affairs Healthcare System, matched by birth year to cisgender men. PSA changes were measured using linear-mixed effects modeling accounting for repeated measures and matching. RESULTS: Non-gonadotrophin releasing hormone (GnRH) agonist or antagonist therapy was associated with 1.30 ng/mL lower PSA (95% confidence interval [CI], 1.14-1.46; P < .001) and GnRH therapy was associated with 1.08 ng/mL lower PSA (95% CI, 0.60-1.55; P < .001) compared with cisgender men. Among 450 TGNB individuals who had undergone PSA testing before and after initiation of hormone therapy, non-GnRH and GnRH therapies resulted in 0.49 ng/mL decrease (95% CI, 0.35-0.62; P < .001) and 0.73 ng/mL decrease (95% CI, 0.43-1.02; P < .001), respectively, from a median baseline of 0.70 ng/mL. From time of age 50 years, TGNB prostate cancer incidence was 1.79 per 1000 patient-years versus 4.02 per 1000 patient-years in cisgender men. CONCLUSIONS: Gender-affirming hormone therapies are associated with significant decreases in PSA, and TGNB individuals assigned male at birth remain at risk of prostate cancer. Future work should establish if a lower threshold for biopsy should be used in these contexts and if the decreased incidence is a result of ascertainment bias or hormone therapy resulting in a true decrease in the incidence of prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California; Center for Health Equity and Education Research (CHEER), La Jolla, California; Veterans Affairs San Diego,…
- Department of Urology, University of California San Diego, La Jolla, California.
- Departments of Radiation Oncology and Population Health Science & Policy, Icahn School of Medicine, New York, New York.
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California.
Zitieren
APA
Morgan, K. M., Deshler, L. N., Tibbs, M. D., Qiao, E. M., Anger, J. T., Salmasi, A., Marshall, D. C., Sanghvi, P., Rose, B. S., & Riviere, P. (2025). Prostate-Specific Antigen and Prostate Cancer in Gender-Affirming Hormone Therapy for Transgender or Nonbinary Individuals. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.09.039
Vancouver
Morgan KM, Deshler LN, Tibbs MD, Qiao EM, Anger JT, Salmasi A, et al. Prostate-Specific Antigen and Prostate Cancer in Gender-Affirming Hormone Therapy for Transgender or Nonbinary Individuals. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2024.09.039
BibTeX
@article{Morgan2025,
author = {Morgan, Kylie M and Deshler, Leah N and Tibbs, Michelle D and Qiao, Edmund M and Anger, Jennifer T and Salmasi, Amirali and Marshall, Deborah C and Sanghvi, Parag and Rose, Brent S and Riviere, Paul},
title = {Prostate-Specific Antigen and Prostate Cancer in Gender-Affirming Hormone Therapy for Transgender or Nonbinary Individuals},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2024.09.039}
}
EUVIMED